Holen Sie sich die Stockscreener-App
101.47
1.12%
-1.15
Schlusskurs vom Vortag:
$102.62
Offen:
$103.68
24-Stunden-Volumen:
612.50K
Relative Volume:
1.10
Marktkapitalisierung:
$8.01B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-425.38M
KGV:
-17.34
EPS:
-5.8504
Netto-Cashflow:
$-275.21M
1W Leistung:
-0.46%
1M Leistung:
-3.76%
6M Leistung:
+10.19%
1J Leistung:
+34.52%
1-Tages-Spanne:
$100.03
$104.42
1-Wochen-Bereich:
$97.77
$104.42
52-Wochen-Spanne:
$63.55
$113.02
Nuvalent Inc Stock (NUVL) Company Profile
Firmenname
Nuvalent Inc
Sektor
Branche
Telefon
508-446-2272
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
101.47 | 8.10B | 0 | -425.38M | -275.21M | -5.8504 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-30 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-12 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-03-14 | Hochstufung | UBS | Neutral → Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-24 | Eingeleitet | UBS | Neutral |
| 2024-08-29 | Eingeleitet | Barclays | Overweight |
| 2024-04-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Fortgesetzt | Guggenheim | Buy |
| 2024-02-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-27 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-24 | Eingeleitet | Guggenheim | Buy |
| 2023-01-18 | Eingeleitet | Wedbush | Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
Alle ansehen
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
Nuvalent CFO Balcom sells $1.13m in company stock - Investing.com
Nuvalent (NUVL) CFO sells 11,430 shares, exercises options under plan - Stock Titan
Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 5,500 Shares of Stock - MarketBeat
Nuvalent Insider Sold Shares Worth $547,524, According to a Recent SEC Filing - marketscreener.com
Nuvalent Insider Sold Shares Worth $545,691, According to a Recent SEC Filing - marketscreener.com
Nuvalent (NUVL) CLO sells shares, exercises options in 10b5-1 plan - Stock Titan
Nuvalent (NUVL) CDO nets 5,500-share sale after option exercise - Stock Titan
Nuvalent (NUVL) Submits NDA to FDA for Neladalkib in ALK-Positive NSCLC - Yahoo Finance
NUVL (NASDAQ) Form 144: Affiliate to sell 16,500 shares via option exercise - Stock Titan
Nuvalent: A Precision Oncology Platform With Two Near-Term Shots On Goal (NASDAQ:NUVL) - Seeking Alpha
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform - BioSpace
Guardant Health partners with Nuvalent on diagnostic tests By Investing.com - Investing.com South Africa
Guardant Health partners with Nuvalent on diagnostic tests - Investing.com
Guardant Health Inc. announces a multi-year strategic partnership with biopharmaceutical company Nuvalent - Bitget
CCORF Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $126 - Moomoo
Pictet Asset Management Holding SA Has $35.78 Million Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent (NUVL) Projected to Post Earnings on Thursday - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $4.70 Million Position in Nuvalent, Inc. $NUVL - MarketBeat
[ARS] Nuvalent, Inc. SEC Filing - Stock Titan
[DEF 14A] Nuvalent, Inc. Definitive Proxy Statement - Stock Titan
Does Nuvalent (NUVL) have the potential to rally 37.26% as Wall Street analysts expect? - MSN
Nuvalent, Inc. (NUVL) Stock Analysis: Exploring a Promising 36% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Leerink Partners Maintains Nuvalent (NUVL) Outperform Recommendation - MSN
Canaccord Genuity Remains a Buy on Nuvalent (NUVL) - The Globe and Mail
Assessing Nuvalent (NUVL) Valuation After FDA Review Progress And New ALK ROS1 Trial Data - Yahoo Finance
NUVL (Nuvalent Inc.) reports wider-than-expected Q4 2025 loss, shares edge 0.26% lower in post-earnings trading.Competitive Risk - Xã Thanh Hà
Trading the Move, Not the Narrative: (NUVL) Edition - Stock Traders Daily
Nuvalent stock presents AACR data ahead of September PDUFA By Investing.com - Investing.com Australia
Nuvalent stock presents AACR data ahead of September PDUFA - Investing.com
NUVL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $155 - GuruFocus
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting - The Malaysian Reserve
HC Wainwright Reaffirms Buy Rating for Nuvalent (NASDAQ:NUVL) - MarketBeat
Nuvalent, Inc. (NUVL) Stock Analysis: Unveiling a 32% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Nuvalent data show activity of ROS1 inhibitor after next-gen TKIs - The Pharma Letter
Benjamin Lane Net Worth (2026) - GuruFocus
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 - Sahm
Nuvalent presents zidesamtinib data in pre-treated lung cancer By Investing.com - Investing.com Australia
Nuvalent presents zidesamtinib data in pre-treated lung cancer - Investing.com
Nuvalent, IncNuvalent Anticipates U.S. Commercial Launch Of Zidesamtinib In 2026 - TradingView
Nuvalent (NUVL) Stock Industry Rotation (Slow Drop) 2026-04-16Institutional Grade Picks - UBND thành phố Hải Phòng
Does FDA Filing For Neladalkib’s ALK-Targeted Lung Cancer Therapy Change The Bull Case For Nuvalent (NUVL)? - simplywall.st
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
Nuvalent (NUVL) CSO Pelish sells $323k in shares By Investing.com - Investing.com Australia
Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 3,093 Shares of Stock - MarketBeat
Finanzdaten der Nuvalent Inc-Aktie (NUVL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):